Court Says Pfizer’s Biosimilar of J&J’s Remicade Doesn’t Infringe Patent

August 17, 2016 10:10 PM

15 0

Court Says Pfizer’s Biosimilar of J&J’s Remicade Doesn’t Infringe Patent

Pfizer Inc. PFE 1.01 % ’s lower-priced version of Johnson & Johnson JNJ 0.81 % ’s blockbuster autoimmune disease drug Remicade doesn’t infringe a patent, a federal court ruled on Wednesday, potentially clearing the way for the drug’s sale in October.

J&J said it would appeal the decision and affirmed its sales projections.

Also read: House Passes Health Bill to Speed Drug Approvals, Boost Biomedical Research

Read more

To category page

Loading...